<--- Back to Details
First PageDocument Content
Pharmaceutical sciences / Pharmacology / Maraviroc / Tropanes / Center for Drug Evaluation and Research / Pfizer / Antiretroviral drug / Dermatologic and Ophthalmic Drugs Advisory Committee / Food and Drug Administration / Chemistry / Clinical research
Date: 2007-04-20 08:28:06
Pharmaceutical sciences
Pharmacology
Maraviroc
Tropanes
Center for Drug Evaluation and Research
Pfizer
Antiretroviral drug
Dermatologic and Ophthalmic Drugs Advisory Committee
Food and Drug Administration
Chemistry
Clinical research

FOOD AND DRUG ADMINISTRATION (FDA) CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING FDA ADVISORS AND CONSULTANTS STAFF CONFERENCE ROOM, RM[removed]FISHERS LANE; ROCKVILLE, MARYL

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 98,97 KB

Share Document on Facebook

Similar Documents

PRESS RELEASE Particle Sciences to Develop Antiretroviral Formulations as part of MOTIF BETHLEHEM, PA- October 10, 2012 ‐ Particle Sciences, a leading drug delivery CRO, has been selected to be the formulation arm of a

PRESS RELEASE Particle Sciences to Develop Antiretroviral Formulations as part of MOTIF BETHLEHEM, PA- October 10, 2012 ‐ Particle Sciences, a leading drug delivery CRO, has been selected to be the formulation arm of a

DocID: 1m6of - View Document

Microsoft Word - Biographie de JF Delfraissy BIS.doc

Microsoft Word - Biographie de JF Delfraissy BIS.doc

DocID: 1gw3d - View Document

Surveillance and outbreak reports  Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy C Semaille ()1, Y Le S

Surveillance and outbreak reports Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy C Semaille ()1, Y Le S

DocID: 1gvMD - View Document

Questioning the HIV-AIDS hypothesis: 30 years of dissent

Questioning the HIV-AIDS hypothesis: 30 years of dissent

DocID: 1gtoc - View Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas

DocID: 1gtlL - View Document